Latest News
-- particles

SELENA+ Highlighted As Part Of National Strategy To Deliver Quality Care

05.03.2020

5 Mar 2020 – In a debate on Singapore Health Ministry's budget for the year, Minister Gan Kim Yong shared the plans to leverage technologies such as artificial Intelligence and robotics to deliver quality care in the nation's ageing and growing population.

One example highlighted by Minister Gan was SELENA+, a deep learning system (DLS) to check for diabetic retinopathy, glaucoma and age-related macular degeneration - all common problems among older people as part of the annual screening program.

SELENA+ will be deployed grade retinal images and flag only those that are abnormal. These images will then be assessed by human graders.

By adopting AI to filter out cases which do not require further attention means more time for humans to focus on more complex cases. Use of Selena+ may go further, said Mr Gan.

SELENA+

 "A predictive risk assessment model for cardiovascular disease will be developed so doctors can accurately identify high-risk patients and conduct more timely interventions to save lives and achieve better outcomes."

Read the full story at:

https://www.moh.gov.sg/news-highlights/details/speech-by-mr-gan-kim-yong-minister-for-health-at-the-ministry-of-health-committee-of-supply-debate-2020-on-thursday-5-march-2020
https://www.straitstimes.com/singapore/health/new-general-and-community-hospital-in-the-east-alexandra-hospital-to-be-redeveloped

About SELENA+
Early screening is highly effective in helping to prevent blindness from a range of eye diseases. SELENA+ is an intelligent deep learning system that can detect eye diseases: this system was jointly invented by researchers at NUS School of Computing (NUS-SoC) and the Singapore Eye Research Institute (SERI) to perform automated image analysis of retinal images. The analysis results will be used to provide early detection of eye diseases, including diabetic retinopathy (DR), glaucoma and age-related macular degeneration (AMD). EyRIS SELENA+

Please direct all queries related to this article to Marketing at info@eyris.io